Lung cancer is a leading cause of cancer deaths worldwide. This retrospective study analyzed 95 patients with stage III-IV non-small cell lung cancer treated with first-line combination chemotherapy and second-line single-agent chemotherapy. The study found that the gemcitabine, platinum-based chemotherapy, and radiotherapy (GPR) regimen had a higher clinical response rate (21.3%) compared to other regimens. Leucopenia and fatigue were common toxicities for first-line treatment, while diarrhea was common for second-line treatment. The study concluded that while no regimen was statistically significantly better, GPR appeared to be more effective with acceptable toxicity.